Journal of Andrology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Published-Ahead-of-Print May 9, 2007, DOI:10.2164/jandrol.107.002790

This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
28/5/734    most recent
Author Manuscript (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Page, S. T
Right arrow Articles by Amory, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Page, S. T
Right arrow Articles by Amory, J. K.

INTRATESTICULAR ANDROGENS AND SPERMATOGENESIS DURING SEVERE GONADOTROPIN SUPPRESSION INDUCED BY MALE HORMONAL CONTRACEPTIVE TREATMENT

Stephanie T Page *, Thomas F Kalhorn , William J. Bremner , Bradley D Anawalt , Alvin M. Matsumoto , and John K. Amory

* To whom correspondence should be addressed. E-mail: page{at}u.washington.edu.

Introduction: Male hormonal contraceptive regimens function by suppressing gonadotropin secretion, resulting in a dramatic decrease in testicular androgen biosynthesis and spermatogenesis. Animal studies suggest that persistent intratesticular (iT-) androgen production has a stimulatory effect on spermatogenesis in the setting of gonadotropin suppression. Objectives: We hypothesized that men with incompletely suppressed spermatogenesis (>1 million sperm/ml) during male hormonal contraceptive treatment would have higher iT-androgen concentrations than men who achieved severe oligospermia (<=1 million sperm/ml). Methods: Twenty healthy men, ages 18-55 years enrolled in a 6-month male contraceptive study of transdermal testosterone (T) gel (100mg/day) + depomedroxyprogesterone acetate (300mg IM/12 wks) with or without the GnRH antagonist, acyline (300µg/kg SC/2 wks x 12 wks) were studied. During the 24th week of treatment, subjects underwent fine needle aspirations of the testes and iT-T and dihydrotestosterone (iT-DHT) were measured in testicular fluid by liquid chromatography-tandem mass spectrometry. Results: All men dramatically suppressed spermatogenesis; 15/20 men were severely oligospermic and 5/20 suppressed to 1.5-3.2 million sperm/ml. In all subjects, mean iT-T and iT-DHT concentrations were 35±8 and 5.1±0.8 nmol/L. IT-androgen concentrations did not significantly differ in men who did and did not achieve severe oligospermia (p=0.41 for iT-T; p=0.18 for iT-DHT). Furthermore, there was no significant correlation between iT-T or iT-DHT and sperm concentration after 24 weeks of treatment. Conclusions: In this study of prolonged gonadotropin suppression induced by male hormonal contraceptive treatment, differences in iT-androgens did not explain differences in spermatogenesis. Additional studies to identify factors involved in persistent spermatogenesis despite gonadotropin suppression are warranted.


Key words: Androgen • Contraception • Spermatogenesis • Testis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by The American Society of Andrology.